HBV VLP
Hepatitis B virus (HBV) virus-like particles (VLPs) are non-infectious particles that mimic the native structure of HBV. These VLPs lack the viral genome, making them a safe and effective platform for vaccine development, diagnostics, and therapeutic research. HBV is a global health concern, causing chronic liver disease, cirrhosis, and hepatocellular carcinoma.
Structure of HBV VLPs
HBV VLPs are composed of the HBV surface antigens (HBsAg), which self-assemble into 22 nm particles resembling the viral envelope.
Key structural components:
- HBsAg Small Surface Protein (S-HBs): Essential for particle assembly and the primary antigen in current HBV vaccines.
- HBsAg Medium (M-HBs) and Large Surface Proteins (L-HBs): May be included in engineered VLPs to enhance immunogenicity.
- Lipid Membrane: Derived from the host cell, providing a native-like environment for the surface proteins.
Production Systems
HBV VLPs are widely produced in several host systems:
- Yeast Systems (e.g., Saccharomyces cerevisiae): The most commonly used platform for commercial HBV vaccines (e.g., Engerix-B, Recombivax HB).
- Mammalian Cells: Enable post-translational modifications similar to native HBV.
- Insect Cells: Suitable for producing complex VLPs, especially those containing multiple surface antigens.
- Plant-Based Systems: Emerging as cost-effective platforms for HBV VLP production.
Applications
- Vaccines
- Prophylactic Vaccines: HBV VLP-based vaccines have been highly successful in preventing HBV infection. Commercially available vaccines, such as Engerix-B and Recombivax HB, are based on yeast-expressed HBsAg VLPs.
- Therapeutic Vaccines: Engineered HBV VLPs are under development to treat chronic HBV infection by enhancing cellular immune responses.
- Diagnostics
- HBV VLPs serve as antigens in diagnostic assays for detecting HBsAg or anti-HBs antibodies in blood samples, aiding in the diagnosis and monitoring of HBV infection.
- Therapeutic Delivery Platforms
- HBV VLPs are being explored as delivery vehicles for therapeutic agents, including RNA-based drugs and immune modulators.
HBV virus-like particles have revolutionized the prevention of hepatitis B, forming the backbone of highly effective vaccines. With ongoing advancements, they hold promise for improved diagnostics, therapeutic vaccines, and innovative drug delivery systems, making them invaluable in the fight against HBV.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|